The impact of induction and/or concurrent chemoradiotherapy on acute and late patient-reported symptoms in oropharyngeal cancer: Application of a mixed-model analysis of a prospective observational cohort registry
Autor: | Kennedy Steele, Katherine A. Hutcheson, Abdallah S.R. Mohamed, David I. Rosenthal, Stephen Y. Lai, Clifton D. Fuller, Jeffrey N. Myers, Lisanne V. van Dijk, Amy C. Moreno, Lance A McCoy, Eva Jones, Adam S. Garden, Christina Setareh Sharafi, Renata Ferrarotto |
---|---|
Rok vydání: | 2021 |
Předmět: |
Oncology
mixed models Cancer Research medicine.medical_specialty Nausea medicine.medical_treatment Cetuximab chemotherapy patient‐ 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Mucositis Humans 030212 general & internal medicine Patient Reported Outcome Measures Registries Chemotherapy business.industry Head and neck cancer Cancer Induction chemotherapy radiation oncology Chemoradiotherapy Original Articles medicine.disease rated toxicities Head and Neck Disease Carboplatin Radiation therapy Oropharyngeal Neoplasms chemistry 030220 oncology & carcinogenesis symptoms Original Article head and neck cancer medicine.symptom Disease Site business patient‐rated toxicities |
Zdroj: | Cancer Cancer, 127(14), 2453-2464. Wiley |
ISSN: | 1097-0142 0008-543X |
Popis: | BACKGROUND The goal of this study was to comprehensively investigate the association of chemotherapy with trajectories of acute symptom development and late symptom recovery in patients with oropharyngeal cancer (OPC) by comparing symptom burden between induction chemotherapy followed by concurrent chemoradiotherapy (ICRT), concurrent chemo‐radiotherapy (CRT), or radiotherapy (RT) alone. METHODS Among a registry of 717 patients with OPC, the 28‐item patient‐reported MD Anderson Symptom Inventory–Head and Neck Module (MDASI‐HN) symptoms were collected prospectively at baseline, weekly during RT, and 1.5, 3 to 6, 12, and 18 to 24 months after RT. The effect of the treatment regimen (ICRT, CRT, and RT alone) was examined with mixed‐model analyses for the acute and late period. In the CRT cohort, the chemotherapy agent relationship with symptoms was investigated. RESULTS Chemoradiation (ICRT/CRT) compared with RT alone resulted in significantly higher acute symptom scores in the majority of MDASI‐HN symptoms (ie, 21 out of 28). No late symptom differences between treatment with or without chemotherapy were observed that were not attributable to ICRT. Nausea was lower for CRT with carboplatin than for CRT with cisplatin; cetuximab was associated with particularly higher scores for acute and late skin, mucositis, and 6 other symptoms. The addition of ICRT compared with CRT or RT alone was associated with a significant increase in numbness and shortness of breath. CONCLUSION The addition of chemotherapy to definitive RT for OPC patients was associated with significantly worse acute symptom outcomes compared with RT alone, which seems to attenuate in the late posttreatment period. Moreover, induction chemotherapy was specifically associated with worse numbness and shortness of breath during and after treatment. LAY SUMMARY Chemotherapy is frequently used in addition to radiotherapy cancer treatment, yet the (added) effect on treatment‐induced over time is not comprehensively investigatedThis study shows that chemotherapy adds to the symptom severity reported by patients, especially during treatment Induction/concurrent chemotherapy significantly augments patient‐reported symptom burden of radiotherapy among patients with oropharyngeal cancer, as worse acute symptom outcomes are observed compared with radiotherapy alone. Induction chemotherapy is associated with greater numbness and shortness of breath during and after treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |